Hematologic Malignancies – Selinexor

Area of TherapyPhase IPhase IIPhase III
Multiple Myeloma (penta-refractory) | STORM

Rights : XPOVIO (selinexor) is approved in the U.S. in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody

Approved
Multiple Myeloma (relapsed/refractory) | BOSTON
Phase I
Phase II
Phase III
Multiple Myeloma (relapsed/refractory and front-line) | STOMP
Phase I
Phase II
Phase III
Diffuse Large B-cell Lymphoma DLBCL (relapsed/refractory) | SADAL

Rights : XPOVIO (selinexor) is approved in the U.S. for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy

Approved
Diffuse Large B-cell Lymphoma (combination with rituximab-gemcitabine-dexamethasone-platinum (R-GDP)) | XPORT-DLBCL-030
Phase I
Phase II
Phase III
Diffuse Large B-cell Lymphoma (combination with chemo and non-chemo regimens) | XPORT-DLBCL-025

Rights : Expected to start in 2020.

Phase I
Phase II
Phase III
Myelofibrosis (previously treated) | XPORT-MF-035
Phase I
Phase II
Phase III
Myelofibrosis (combination with ruxolitinib)| XPORT-MF-034
Phase I
Phase II
Phase III

Solid Tumor Malignancies – Selinexor

Glioblastoma Multiforme (GBM) – Selinexor

Area of TherapyPhase IPhase IIPhase III
Glioblastoma | KING
Phase I
Phase II
Phase III
Glioblastoma (combination with active agents / newly diagnosed or recurrent) | XPORT-GBM-029
Phase I
Phase II
Phase III

Additional Oncology Programs – Eltanexor and KPT-9274

Area of TherapyPhase IPhase IIPhase III
Myelodysplastic Syndromes (MDS)(single agent or in combination with hypomethylating agents)

Rights : Drug: Eltanexor / Combination study expected to start in 2020.

Phase I
Phase II
Phase III
Colorectal Cancer (CRC) and Prostate Cancer (PrC)

Rights : Drug: Eltanexor

Phase I
Phase II
Phase III
Solid Tumors

Rights : Drug: KPT-9274

Phase I
Phase II
Phase III

Other Indications

Area of TherapyPhase IPhase IIPhase III

Other Indications

Severe COVID-19

Rights : Drug: Selinexor

Phase I
Phase II
Phase III

Partnerships

antegene-logo

Antegene licensed rights to selinexor, eltanexor, verdinexor, and KPT-9274 in China, South Korea, Australia and additional Asia Pacific markets, excluding Japan.

Anivive holds exclusive worldwide rights to research, develop, and commercialize verdinexor only for the treatment of cancer in companion animals